187 related articles for article (PubMed ID: 38369502)
21. Oncolytic adenovirus decreases the proportion of TIM-3
Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
[TBL] [Abstract][Full Text] [Related]
22. LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.
Keane C; Law SC; Gould C; Birch S; Sabdia MB; Merida de Long L; Thillaiyampalam G; Abro E; Tobin JW; Tan X; Xu-Monette ZY; Young KH; Gifford G; Gabreilli S; Stevenson WS; Gill A; Talaulikar D; Jain S; Hernandez A; Halliday SJ; Bird R; Cross D; Hertzberg M; Gandhi MK
Blood Adv; 2020 Apr; 4(7):1367-1377. PubMed ID: 32267932
[TBL] [Abstract][Full Text] [Related]
23. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
[TBL] [Abstract][Full Text] [Related]
24. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
25. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
26. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
27. Programmed cell death-ligand 1 (PD-L1)
Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
[TBL] [Abstract][Full Text] [Related]
28. Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer.
Liu JF; Wu L; Yang LL; Deng WW; Mao L; Wu H; Zhang WF; Sun ZJ
J Exp Clin Cancer Res; 2018 Mar; 37(1):44. PubMed ID: 29506555
[TBL] [Abstract][Full Text] [Related]
29. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
[TBL] [Abstract][Full Text] [Related]
30. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
32. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
33. The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Kandel S; Adhikary P; Li G; Cheng K
Cancer Lett; 2021 Jul; 510():67-78. PubMed ID: 33895262
[TBL] [Abstract][Full Text] [Related]
34. Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.
Liu J; Zhang S; Hu Y; Yang Z; Li J; Liu X; Deng L; Wang Y; Zhang X; Jiang T; Lu X
J Immunother; 2016 May; 39(4):171-80. PubMed ID: 27070448
[TBL] [Abstract][Full Text] [Related]
35. Association between Tim‑3 and Gal‑9 expression and gastric cancer prognosis.
Wang Y; Zhao E; Zhang Z; Zhao G; Cao H
Oncol Rep; 2018 Oct; 40(4):2115-2126. PubMed ID: 30106451
[TBL] [Abstract][Full Text] [Related]
36. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system.
Liu B; Yan S; Li S; Zhang Q; Yang M; Yang L; Ma J; Li X
Pathol Res Pract; 2022 Nov; 239():154008. PubMed ID: 36183436
[TBL] [Abstract][Full Text] [Related]
37. Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer.
Zhang L; Chen Y; Wang H; Xu Z; Wang Y; Li S; Liu J; Chen Y; Luo H; Wu L; Yang Y; Zhang H; Peng H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34140315
[TBL] [Abstract][Full Text] [Related]
38. TIM3/CEACAM1 pathway involves in myeloid-derived suppressor cells induced CD8
Yu S; Ren X; Meng F; Guo X; Tao J; Zhang W; Liu Z; Fu R; Li L
Immunology; 2023 Feb; 168(2):273-289. PubMed ID: 35470423
[TBL] [Abstract][Full Text] [Related]
39. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
40. High co-expression of immune checkpoint receptors PD-1, CTLA-4, LAG-3, TIM-3, and TIGIT on tumor-infiltrating lymphocytes in early-stage breast cancer.
Mollavelioglu B; Cetin Aktas E; Cabioglu N; Abbasov A; Onder S; Emiroglu S; Tükenmez M; Muslumanoglu M; Igci A; Deniz G; Ozmen V
World J Surg Oncol; 2022 Oct; 20(1):349. PubMed ID: 36271406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
